Ionis Pharmaceuticals (IONS) Competitors $63.85 -0.15 (-0.24%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, INCY, NBIX, UTHR, BMRN, EXEL, MDGL, EXAS, HALO, and RGENShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Its Competitors Biogen Incyte Neurocrine Biosciences United Therapeutics BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Exact Sciences Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Which has preferable earnings and valuation, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.26$1.63B$10.4614.23Ionis Pharmaceuticals$944.05M10.78-$453.90M-$1.84-34.70 Does the media refer more to BIIB or IONS? In the previous week, Ionis Pharmaceuticals had 1 more articles in the media than Biogen. MarketBeat recorded 28 mentions for Ionis Pharmaceuticals and 27 mentions for Biogen. Biogen's average media sentiment score of 1.42 beat Ionis Pharmaceuticals' score of 0.83 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 20 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 12 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in BIIB or IONS? 87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate BIIB or IONS? Biogen presently has a consensus target price of $181.65, indicating a potential upside of 22.05%. Ionis Pharmaceuticals has a consensus target price of $67.88, indicating a potential upside of 6.31%. Given Biogen's higher probable upside, research analysts clearly believe Biogen is more favorable than Ionis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.32Ionis Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.81 Is BIIB or IONS more profitable? Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Ionis Pharmaceuticals -28.25%-45.29%-8.99% Which has more volatility & risk, BIIB or IONS? Biogen has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. SummaryBiogen beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.20B$2.55B$5.78B$10.07BDividend YieldN/A56.65%5.69%4.62%P/E Ratio-34.7023.7675.0426.20Price / Sales10.78564.68469.7391.86Price / CashN/A169.2537.0859.91Price / Book17.125.3912.236.28Net Income-$453.90M$32.95M$3.29B$270.85M7 Day Performance4.28%2.61%1.53%3.58%1 Month Performance54.18%9.87%7.86%6.67%1 Year Performance55.65%1.49%63.05%27.74% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals3.6423 of 5 stars$63.85-0.2%$67.88+6.3%+50.6%$10.20B$944.05M-34.701,069Insider TradeBIIBBiogen4.6557 of 5 stars$132.22-0.3%$185.74+40.5%-25.2%$19.39B$9.68B12.647,605Positive NewsINCYIncyte4.7793 of 5 stars$84.61+1.1%$81.60-3.6%+36.5%$16.52B$4.58B19.232,617Positive NewsShort Interest ↓NBIXNeurocrine Biosciences4.7318 of 5 stars$139.60+0.5%$159.50+14.3%+18.2%$13.85B$2.36B41.301,800Positive NewsUTHRUnited Therapeutics4.7605 of 5 stars$304.76-0.8%$382.00+25.3%+16.9%$13.75B$2.88B11.901,305News CoveragePositive NewsAnalyst ForecastInsider TradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.9525 of 5 stars$58.27+1.0%$93.17+59.9%-34.1%$11.19B$3.06B17.293,040Short Interest ↑EXELExelixis4.7283 of 5 stars$37.42-1.3%$44.06+17.7%+46.7%$10.07B$2.23B17.991,147MDGLMadrigal Pharmaceuticals4.1739 of 5 stars$437.85+0.2%$459.25+4.9%+88.6%$9.72B$180.13M-34.0790Positive NewsInsider TradeEXASExact Sciences4.7995 of 5 stars$47.42+1.0%$67.05+41.4%-12.7%$8.98B$2.76B-8.737,000Positive NewsAnalyst ForecastShort Interest ↓Analyst RevisionHALOHalozyme Therapeutics4.5999 of 5 stars$73.15+0.5%$67.11-8.3%+30.5%$8.56B$1.02B16.74390Positive NewsInsider TradeRGENRepligen4.9071 of 5 stars$122.32+0.1%$169.45+38.5%-16.7%$6.88B$634.44M-489.261,778Positive NewsAnalyst Forecast Related Companies and Tools Related Companies BIIB Competitors INCY Competitors NBIX Competitors UTHR Competitors BMRN Competitors EXEL Competitors MDGL Competitors EXAS Competitors HALO Competitors RGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IONS Stock Alerts